Berlin - Delayed Quote EUR

BioXcel Therapeutics Inc (BX2.BE)

0.3046

-0.0065

(-2.09%)

As of 8:00:48 AM GMT+1. Market Open.

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

BTAI
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase up to 5,600,000 shares of Common Stock, and, in lieu the

GlobeNewswire 2 months ago

BTAI
BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase shares of Common Stock, and, in lieu thereof to certain inv

GlobeNewswire 2 months ago

BTAI
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BioXcel Therapeutics Inc (BTAI) reports significant progress in pivotal trials and improved financial metrics despite revenue challenges.

GuruFocus.com 2 months ago

BTAI
Q3 2024 BioXcel Therapeutics Inc Earnings Call

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

BTAI
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

BTAI
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. “Our focus continues t

GlobeNewswire 2 months ago

BTAI
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer’s dementia (AAD) Estimated 140 million annual acute agitation episodes associated with these conditions 1-3 NEW HAVEN, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizin

GlobeNewswire 2 months ago

BTAI
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2024 financial results on Thursday, November 14, 2024, before the open of the U.S. financial markets. The Company’s management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these results and provid

GlobeNewswire 2 months ago

BTAI
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

BTAI
BioXcel Therapeutics to Present at ThinkEquity Conference

NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO, and Vincent J. O’Neill, M.D., Executive Vice President, Chief of Product Development and Medical Officer, will present at the ThinkEquity Conference in New York City. The presentation is set for Wednesday, October 30 at 2 p.m. ET. To access a l

GlobeNewswire 3 months ago

BTAI
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded stress-related trial for BXCL501 NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced a collaboration with the University of North Carol

GlobeNewswire 3 months ago

BTAI
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated with Alzheimer’s dementia Company to maintain IGALMI™ in the market without current commercial infrastructure NEW HAVEN, Conn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop

GlobeNewswire 4 months ago

BTAI
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Estimated 23 million annual agitation episodes in the at-home setting 1-3 No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders or schizophrenia NEW HAVEN, Conn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced the initiation of patient enrollment in its SE

GlobeNewswire 4 months ago

BTAI
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BioXcel Therapeutics (BTAI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 4 months ago

BTAI
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

NEW HAVEN, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference in Boston on Tuesday, August 13, 2024 at 1 p.m. ET. Dr. Mehta will be joined by Vincent J. O’Neill, M.D., Exe

GlobeNewswire 5 months ago

BTAI
Q2 2024 BioXcel Therapeutics Inc Earnings Call

Q2 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

BTAI
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 72.37% and 38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

BTAI
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

Planning initiation of SERENITY At-Home pivotal Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Advancing plans for TRANQUILITY In-Care pivotal Phase 3 trial with BXCL501 for agitation associated with Alzheimer’s dementia Reported positive topline results from IGALMI™ post-marketing requirement (PMR) study Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:

GlobeNewswire 5 months ago

BTAI
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the open of the U.S. financial markets. The Company’s management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these r

GlobeNewswire 5 months ago

BTAI

Performance Overview

Return	BX2.BE	S&P 500
YTD	-18.40%	+2.78%
1-Year	-90.20%	+23.27%
3-Year	-97.71%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioXcel Therapeutics Inc (BX2.BE)

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

Q3 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

Q2 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

Performance Overview